Journal of Internal Medicine Concepts & Practice >

2022 , Vol. 17 >Issue 05: 392 - 395

DOI: https://doi.org/10.16138/j.1673-6087.2022.05.009

Review article

Research progress of percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation

Expand

Received date: 2022-03-02

  Online published: 2022-11-04

Fold

Cite this article

YIN Xiang, ZHENG Liangrong . Research progress of percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation[J]. Journal of Internal Medicine Concepts & Practice, 2022 , 17(05) : 392 -395 . DOI: 10.16138/j.1673-6087.2022.05.009

References

[1] 周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志, 2004, 43(7): 491-494.
[2] Cresti A, García-Fernández MA, Sievert H, et al. Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study[J]. EuroIntervention, 2019, 15(3): e225-e230.
[3] Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE)[J]. Circulation, 2021, 144(19): 1543-1552.
[4] Galea R, Mahmoudi K, Gräni C, et al. Watchman FLX vs. watchman 2.5 in a dual-center left atrial appendage closure cohort[J]. Europace, 2022.[Epub ahead of print].
[5] Galea R, De Marco F, Meneveau N, et al. Amulet or Watchman device for percutaneous left atrial appendage closure[J]. Circulation, 2022, 145(10): 724-738.
[6] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus Warfarin therapy for prevention of stroke in patients with atrial fibrillation[J]. Lancet, 2009, 374(9689): 534-542.
[7] Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure[J]. Circulation, 2011, 123(4): 417-424.
[8] Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy[J]. J Am Coll Cardiol, 2014, 64(1): 1-12.
[9] Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure[J]. J Am Coll Cardiol, 2017, 70(24): 2964-2975.
[10] Godino C, Melillo F, Bellini B, et al. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk[J]. EuroIntervention, 2020, 15(17): 1548-1554.
[11] Nielsen-Kudsk JE, Korsholm K, Damgaard D, et al. Cli-nical outcomes associated with left atrial appendage occlu-sion versus direct oral anticoagulation in atrial fibrillation[J]. JACC Cardiovasc Interv, 2021, 14(1): 69-78.
[12] Osmancik P, Tousek P, Herman D, et al. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)[J]. Am Heart J, 2017, 183: 108-114.
[13] Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol, 2020, 75(25): 3122-3135.
[14] Osmancik P, Herman D, Neuzil P, et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation[J]. J Am Coll Cardiol, 2022, 79(1): 1-14.
[15] Price MJ, Slotwiner D, Du C, et al. Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States[J]. JACC Cardiovasc Interv, 2022, 15(7): 741-750.
[16] Boersma LV, Ince H, Kische S, et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the Watchman left atrial appendage closure technology[J]. Circ Arrhythm Electrophysiol, 2019, 12(4): e006841.
[17] Aonuma K, Yamasaki H, Nakamura M, et al. Efficacy and safety of left atrial appendage closure with Watchman in Japanese nonvalvular atrial fibrillation patients[J]. Circ J, 2020, 84(8): 1237-1243.
[18] Phillips KP, Santoso T, Sanders P, et al. Left atrial appendage closure with Watchman in Asian patients[J]. Int J Cardiol Heart Vasc, 2019, 23: 100358.
[19] Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation[J]. J Am Coll Cardiol, 2013, 61(25): 2551-2556.
[20] Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy[J]. EuroIntervention, 2017, 12(17): 2075-2082.
[21] Fauchier L, Cinaud A, Brigadeau F, et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation[J]. J Am Coll Cardiol, 2018, 71(14): 1528-1536.
[22] Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion[J]. Europace, 2020, 22(2): 184.
[23] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国左心耳封堵预防心房颤动卒中专家共识(2019)[J]. 中华心血管病杂志, 2019(12): 937-938.
[24] Enomoto Y, Gadiyaram VK, Gianni C, et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device[J]. Heart Rhythm, 2017, 14(1): 19-24.
[25] Bergmann MW, Betts TR, Sievert H, et al. Safety and efficacy of early anticoagulation drug regimens after Watchman left atrial appendage closure[J]. EuroIntervention, 2017, 13(7): 877-884.
[26] Saw J, Nielsen-Kudsk JE, Bergmann M, et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure[J]. JACC Cardiovasc Interv, 2019, 12(11): 1067-1076.
[27] Merkulova I, Pevzner D, Rytova Y, et al. Antithrombotic treatment after the left atrial appendage occlusion: impact on clinical outcomes in russian prospective registry[J]. J Am Coll Cardiol, 2022, 79(9): 795.
[28] Li X, Zhang X, Jin Q, et al. Clinical efficacy and safety comparison of rivaroxaban and dabigatran for nonvalvular atrial fibrillation patients undergoing percutaneous left atrial appendage closure operation[J]. Front Pharmacol, 2021, 12: 614762.
[29] Duthoit G, Silvain J, Marijon E, et al. Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure[J]. Circ Cardiovasc Interv, 2020, 13(7): e8481.
Options
Outlines

/

〈 〉